TheraCyte
Advancing Cell Therapy through Engineered Cell Encapsulation

Turning engineered cells into viable treatments requires more than developing cells with a desired function. Once implanted, those cells must survive the body’s immune response while receiving nutrients and releasing therapeutic molecules. TheraCyte’s encapsulation technology was developed at Baxter Healthcare Corporation over roughly a decade, with approximately $30 million invested in its development. Since becoming an independent company in 1999, TheraCyte has focused on supplying the technology to outside researchers, allowing scientists to investigate cellbased therapies without developing their own encapsulation devices.

“Our device protects cells from the body’s immune response while allowing nutrients and therapeutic molecules to pass through and support continued cellular function,” says Paul Quadros, Chairman.

TheraCyte’s encapsulation technology combines multiple layers of biocompatible membranes to create a protective environment for engineered cells. The membrane structure allows nutrients to reach the enclosed cells and therapeutic molecules to pass into the surrounding tissue, supporting the cells’ intended function after implantation.

Following implantation beneath the skin, blood vessels develop close to the membranes, bringing nutrients near the encapsulated cells. Therapeutic proteins and other molecules produced by the cells can then pass outward through the membrane structure. The design combines protection from the recipient’s immune response with the exchange needed to sustain cellular activity.

Expanding Applications across Cell Therapy Research

Rather than developing cell therapies of its own, TheraCyte supplies encapsulation devices to researchers investigating engineered cells. Quadros explains that many companies reserve their encapsulation technologies for proprietary therapeutic programs. TheraCyte, by contrast, makes its devices available to academic laboratories and pharmaceutical companies pursuing different cell-based applications.

Access to an established encapsulation platform allows scientists to investigate whether engineered cells perform as intended in animal models without first having to develop a separate protective device. The company reports that its technology has been used in hundreds, and possibly thousands, of animal studies, while dozens of peer-reviewed journal articles have documented research using the devices.

Diabetes has historically attracted the greatest research interest, although investigators have explored applications across other areas of medicine. The researchers determine which cells to investigate and how to assess their therapeutic potential, while TheraCyte provides the device used to encapsulate them.

Supporting the Path Toward Clinical Development

The technology also has a history of human clinical investigation. According to Quadros, while it was still at Baxter, TheraCyte devices were implanted in approximately 50 people and used in two human clinical trials. He reports that the devices demonstrated their intended function in humans for periods of up to one year. The experience provides a foundation for continued research and supports TheraCyte’s work with customers exploring cellbased therapies for future clinical applications.

TheraCyte currently supplies devices for research purposes rather than manufacturing them for human clinical use. For customers seeking to advance engineered cell products into human trials, the company is prepared to support arrangements for good manufacturing practice (GMP) production and engagement with relevant regulatory authorities. It also makes a 35-page white paper on the device’s human-use history available to organizations considering clinical development.

Research requirements vary, so TheraCyte offers customized device configurations. Previous adaptations have included internal channels and subchambers, allowing the design to accommodate different needs while retaining the underlying encapsulation technology.

The company does not currently plan to change the device’s fundamental technology or materials. Instead, it continues to supply the established platform and adapt configurations where needed, leaving scientists to develop the engineered cells and investigate their therapeutic applications.

TheraCyte’s contribution lies in making encapsulation technology available beyond its own organization, giving independent research teams a means to investigate engineered cells without having to create their own protective devices. Its combination of an established platform, adaptable configurations and experience supporting research distinguishes its role from that of companies focused on developing proprietary therapies. As researchers explore new cell-based treatments, TheraCyte provides the specialized technology that supports their investigations, underpinning its recognition as Top Cell Encapsulation Systems Manufacturer 2026.